A long progression free survival time in a patient with metastatic neuroendocrine neoplasm of small intestine after treatment with long-acting octreotide and peptide receptor radionuclide therapy

Abstract

Long-acting somatostatin analogs are considered as a first line of treatment in well-differentiated metastatic gastroenteropancreatic neuroendocrine neoplasms with symptoms of carcinoid syndrome, because of relief symptoms and antiproliferative effect. According to the results of PROMID study (Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors), median time to progression is 14.3 months during treatment with octreotide. In this case report we presented 46-year-old woman with primary diagnosis of hepatocellular carci­noma, treated with palliative chemiotherapy (doxorubicin, dexamethasone, cyclophosphamide) with hematologic side effects and after that in follow-up. Because of uncommon course of HCC, histopathology examination was reviewed. The new diagnosis was metastases of well-differentiated neuroendocrine tumor (G1 in WHO 2010 clas­sification). During diagnostic imaging (computed tomography of chest and abdomen, Gallium-68-DOTA-TATE PET/CT) primary tumor in small intestine was found. The final diagnosis was well-differentiated neuroendocrine neoplasm of small intestine with distant metastasis and carcinoid syndrome. Improvement of general condition and 26 months stabilization of the disease was observed after concomitant treatment with long-acting octreotide and peptide receptor radionuclide therapy.